HRT Financial’s Estrella Immunopharma ESLA Stock Holding History

HRT Financial’s Portfolio ESLA Stock Details ESLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-17,266	Closed	-$14K	–	3056
2025 Q2	$14K	Buy	+17,266	New	+$16.7K	﹤0.01%	2427

Other funds holding ESLA

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

ASM

ATW SPAC Management New York $79.2M AUM 10.67% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

MCP

Maso Capital Partners Hong Kong $60.9M AUM 0.32% 1-Year Est. Return

HRT Financial's ESLA Position: Q3 2025 in Review

HRT Financial sold out of Estrella Immunopharma (ESLA) in Q3 2025, closing a stake of 17,266 shares — an estimated $14K sold.

HRT Financial first reported a position in ESLA in Q2 2025 and held it in 1 quarter. The position peaked at $14K in Q2 2025. 13 funds tracked by Wall St. Rank hold ESLA as of Q3 2025.

HRT Financial reported no remaining Estrella Immunopharma position as of Q3 2025 after selling out during the quarter.
HRT Financial sold 17,266 Estrella Immunopharma shares in Q3 2025, an estimated $14K.
HRT Financial first reported a position in Estrella Immunopharma in Q2 2025 and held it in 1 quarter.
HRT Financial's Estrella Immunopharma position peaked at $14K in Q2 2025.
13 funds tracked by Wall St. Rank held Estrella Immunopharma as of Q3 2025.

Based on HRT Financial's 13F filing for Q3 2025, filed 14 Nov 2025.